Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Maxwell Brown, Rza Abasov, David Salerno, Tsiporah B. Shore, Usama Gergis, Sebastian Mayer, Adrienne Phillips, Jingmei Hsu, Rosy Priya L. Kodiyanplakkal, Michelle Pasciolla & Koen van Besien. (2020) Impact of alemtuzumab dosing and low-dose total body irradiation on cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation. Leukemia & Lymphoma 61:12, pages 3024-3026.
Read now
Read now
Graham McIlroy, Emmanouil Nikolousis, Nervana Abou-Zeid, Paneesha Shankara, Bhuvan Kishore, Maria Kaparou, Richard Lovell, Shereef Elmoamly, David Davies, Claire Horgan, Amir Shenouda & Alexandros Kanellopoulos. (2020) Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation . Leukemia & Lymphoma 61:1, pages 202-205.
Read now
Read now
Articles from other publishers (28)
Daniele Avenoso, Varun Mehra, Liron Barnea Slonim, Madson de Farias, Hassan Alshehri, Styliani Bouziana, Pramila Krishnamurthy, Austin Kulasekararaj, Francesco Dazzi, Henry Wood, Michelle Kenyon, Ye Ting Leung, Sandra Anteh, Mili Naresh Shah, Guy Hannah, Fabio Serpenti, Amna Gameil, Christianne Bourlon, Oana Diana Dragoi, Antonio Pagliuca & Victoria Potter. (2023) Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. Transplantation and Cellular Therapy 29:11, pages 698.e1-698.e6.
Crossref
Crossref
Masahiro Yasunaga. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
31
.
Edouard Forcade, Sylvie Chevret, Jürgen Finke, Gerhard Ehninger, Francis Ayuk, Dietrich Beelen, Linda Koster, Arnold Ganser, Liisa Volin, Henrik Sengeloev, Mauricette Michallet, Johanna Tischer, Pavel Jindra, Maria Jesús Pascual Cascon, Yener Koc, Mutlu Arat, Agnieszka Tomaszewska, Patrick Hayden, Theo de Witte, Ibrahim Yakoub-Agha, Nicolaus Kröger & Marie Robin. (2022) Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation 57:5, pages 768-774.
Crossref
Crossref
Eudocia Q. Lee. 2022. Neurological Complications of Systemic Cancer and Antineoplastic Therapy. Neurological Complications of Systemic Cancer and Antineoplastic Therapy
501
513
.
Tor Henrik Anderson Tvedt, Anh Khoi Vo, Øystein Bruserud & Håkon Reikvam. (2021) Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences. Journal of Clinical Medicine 10:21, pages 5190.
Crossref
Crossref
Lev Gorfinkel, Carolyn Demsky, Farzana Pashankar, Gary Kupfer & Niketa C. Shah. (2021) Bone marrow transplant using fludarabine‐based reduced intensity conditioning regimen with in vivo T cell depletion in patients with Fanconi anemia. Pediatric Transplantation 25:4.
Crossref
Crossref
Athena L. Russell, Chengyu Prince, Taran S. Lundgren, Kristopher A. Knight, Gabriela Denning, Jordan S. Alexander, Jaquelyn T. Zoine, H. Trent Spencer, Shanmuganathan Chandrakasan & Christopher B. Doering. (2021) Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII. Molecular Therapy - Methods & Clinical Development 21, pages 710-727.
Crossref
Crossref
Joshua Pecoraro & Hillard M. Lazarus. 2021. Blood and Marrow Transplant Handbook. Blood and Marrow Transplant Handbook
153
186
.
Pascal Woelfinger, Katharina Epp, Lukas Schaefer, Diana Kriege, Matthias Theobald, Tobias Bopp & Eva‐Maria Wagner‐Drouet. (2020) CD52‐negative T cells predict acute graft‐versus‐host disease after an alemtuzumab‐based conditioning regimen. British Journal of Haematology 191:2, pages 253-262.
Crossref
Crossref
Vikas Chander & Gurudutta Gangenahalli. (2020) Emerging strategies for enhancing the homing of hematopoietic stem cells to the bone marrow after transplantation. Experimental Cell Research 390:1, pages 111954.
Crossref
Crossref
Rick Admiraal, Cornelia M. Jol-van der Zijde, Juliana M. Furtado Silva, Catherijne A. J. Knibbe, Arjan C. Lankester, Jaap Jan Boelens, Goeff Hale, Aniekan Etuk, Melanie Wilson, Stuart Adams, Paul Veys, Charlotte van Kesteren & Robbert G. M. Bredius. (2019) Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome. Clinical Pharmacokinetics 58:12, pages 1609-1620.
Crossref
Crossref
Tsubasa Okano, Kohsuke Imai, Yuki Tsujita, Noriko Mitsuiki, Kenichi Yoshida, Chikako Kamae, Kenichi Honma, Kanako Mitsui-Sekinaka, Yujin Sekinaka, Tamaki Kato, Katsuyuki Hanabusa, Eri Endo, Takehiro Takashima, Haruka Hiroki, Tzu-Wen Yeh, Keisuke Tanaka, Masakazu Nagahori, Ikuya Tsuge, Yuki Bando, Fuminori Iwasaki, Yoshiaki Shikama, Masami Inoue, Tomiko Kimoto, Naohiko Moriguchi, Yuki Yuza, Takashi Kaneko, Kyoko Suzuki, Tomoyo Matsubara, Yoshihiro Maruo, Tomoaki Kunitsu, Tomoko Waragai, Hideki Sano, Yuko Hashimoto, Kazuhiro Tasaki, Osamu Suzuki, Toshihiko Shirakawa, Motohiro Kato, Toru Uchiyama, Masataka Ishimura, Tetsuzo Tauchi, Hiroshi Yagasaki, Shiann-Tarng Jou, Hsin-Hui Yu, Hirokazu Kanegane, Sven Kracker, Anne Durandy, Daiei Kojima, Hideki Muramatsu, Taizo Wada, Yuzaburo Inoue, Hidetoshi Takada, Seiji Kojima, Seishi Ogawa, Osamu Ohara, Shigeaki Nonoyama & Tomohiro Morio. (2019) Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase δ syndrome type 1. Journal of Allergy and Clinical Immunology 143:1, pages 266-275.
Crossref
Crossref
Hafiz Muhammad Aslam, Said Yousuf, Adetola Kassim, Shumaila Muhammad Iqbal & Shahrukh K. Hashmi. (2018) Hematopoietic stem cell transplantation for adult sickle cell disease in the era of universal donor availibility. Bone Marrow Transplantation 53:11, pages 1390-1400.
Crossref
Crossref
Matthijs D. Kruizinga, Maarten J.D. van Tol, Vincent Bekker, Tanja Netelenbos, Frans J. Smiers, Dorine Bresters, Anja M. Jansen-Hoogendijk, Monique M. van Ostaijen-ten Dam, Wouter J.W. Kollen, Jaap J. Zwaginga, Arjan C. Lankester & Robbert G.M. Bredius. (2018) Risk Factors, Treatment, and Immune Dysregulation in Autoimmune Cytopenia after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients. Biology of Blood and Marrow Transplantation 24:4, pages 772-778.
Crossref
Crossref
Thomas Neumann, Laila Schneidewind, Thomas Thiele, Daniel Pink, Meike Schulze, Christian Schmidt & William Krüger. (2018) No indication of increased infection rates using low-dose alemtuzumab instead of anti-thymocyte globulin as graft-versus-host disease prophylaxis before allogeneic stem cell transplantation. Transplant Infectious Disease 20:1, pages e12822.
Crossref
Crossref
Robert Ali, Jeremy Ramdial, Sandra Algaze & Amer Beitinjaneh. (2017) The Role of Anti-Thymocyte Globulin or Alemtuzumab-Based Serotherapy in the Prophylaxis and Management of Graft-Versus-Host Disease. Biomedicines 5:4, pages 67.
Crossref
Crossref
Talal Hilal, Stacey Slone, Shawn Peterson, Charles Bodine & Zartash Gul. (2017) Cytomegalovirus reactivation is associated with a lower rate of early relapse in myeloid malignancies independent of in-vivo T cell depletion strategy. Leukemia Research 57, pages 37-44.
Crossref
Crossref
Jeannine S. McCune, Meagan J. Bemer & Janel Long-Boyle. (2015) Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II. Clinical Pharmacokinetics 55:5, pages 551-593.
Crossref
Crossref
Thomas Neumann, Laila Schneidewind, Thomas Thiele, Meike Schulze, Anne F. Klenner, Christoph Busemann, Daniel Pink, Andreas Greinacher, Gottfried Dölken & William H. Krüger. (2016) Reduced platelet transfusions and earlier platelet engraftment using alemtuzumab-based conditioning regimen in allogeneic stem cell transplantation. Journal of Cancer Research and Clinical Oncology 142:5, pages 1091-1097.
Crossref
Crossref
Khilna Patel, Sapna Parmar, Shreya Shah, Tsiporah Shore, Usama Gergis, Sebastian Mayer & Koen van Besien. (2016) Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 22:3, pages 456-461.
Crossref
Crossref
M. M. Chao, J. S. Kuehl, G. Strauss, H. Hanenberg, D. Schindler, H. Neitzel, C. Niemeyer, I. Baumann, H. von Bernuth, J. Rascon, M. Nagy, M. Zimmermann, C. P. Kratz & W. Ebell. (2015) Outcomes of mismatched and unrelated donor hematopoietic stem cell transplantation in Fanconi anemia conditioned with chemotherapy only. Annals of Hematology 94:8, pages 1311-1318.
Crossref
Crossref
Akshat Jain & Indira Sahdev. (2015) Alemtuzumab Pharmacokinetics in Hematopoietic Stem Cell Transplants for Nonmalignant Genetic Diseases. Biology of Blood and Marrow Transplantation 21:7, pages 1337.
Crossref
Crossref
S R Solomon, C A Sizemore, X Zhang, S Brown, H K Holland, L E Morris & A Bashey. (2014) Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial. Bone Marrow Transplantation 49:5, pages 616-621.
Crossref
Crossref
Jonathan P. Lane, Philippa T.G. Evans, Zohreh Nademi, Dawn Barge, Anthony Jackson, Sophie Hambleton, Terry J. Flood, Andrew J. Cant, Mario Abinun, Mary A. Slatter & Andrew R. Gennery. (2014) Low-Dose Serotherapy Improves Early Immune Reconstitution after Cord Blood Transplantation for Primary Immunodeficiencies. Biology of Blood and Marrow Transplantation 20:2, pages 243-249.
Crossref
Crossref
Koen van Besien. (2013) Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence. Hematology 2013:1, pages 56-62.
Crossref
Crossref
Anita J. Kumar, Elizabeth O. Hexner, Noelle V. Frey, Selina M. Luger, Alison W. Loren, Ran Reshef, Jean Boyer, Jacqueline Smith, Edward A. Stadtmauer, Bruce L. Levine, Carl H. June, David L. Porter & Steven C. Goldstein. (2013) Pilot Study of Prophylactic Ex Vivo Costimulated Donor Leukocyte Infusion After Reduced-Intensity Conditioned Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 19:7, pages 1094-1101.
Crossref
Crossref
Pramila Krishnamurthy, Victoria T. Potter, Linda D. Barber, Austin G. Kulasekararaj, Zi Yi Lim, Rachel M. Pearce, Hugues de Lavallade, Michelle Kenyon, Robin M. Ireland, Judith C.W. Marsh, Stephen Devereux, Antonio Pagliuca & Ghulam J. Mufti. (2013) Outcome of Donor Lymphocyte Infusion after T Cell–depleted Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation 19:4, pages 562-568.
Crossref
Crossref
Rob S Sellar & Karl S Peggs. (2012) Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation. Future Oncology 8:12, pages 1549-1565.
Crossref
Crossref